A polymorphism in HLA-G modifies statin benefit in asthma
Brilliant, Murray H
Kitchner, Terrie E
Linneman, James G
Roden, Dan M
Shaffer, Christian M
Medina, Marisa WNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationNaidoo, D., A. C. Wu, M. H. Brilliant, J. Denny, C. Ingram, T. E. Kitchner, J. G. Linneman, et al. 2014. “A polymorphism in HLA-G modifies statin benefit in asthma.” The pharmacogenomics journal 15 (3): 272-277. doi:10.1038/tpj.2014.55. http://dx.doi.org/10.1038/tpj.2014.55.
AbstractSeveral reports have shown that statin treatment benefits patients with asthma, however inconsistent effects have been observed. The mir-152 family (148a, 148b and 152) has been implicated in asthma. These microRNAs suppress HLA-G expression, and rs1063320, a common SNP in the HLA-G 3’UTR which is associated with asthma risk, modulates miRNA binding. We report that statins up-regulate mir-148b and 152, and affect HLA-G expression in an rs1063320 dependent fashion. In addition, we found that individuals who carried the G minor allele of rs1063320 had reduced asthma related exacerbations (emergency department visits, hospitalizations or oral steroid use) compared to non-carriers (p=0.03) in statin users ascertained in the Personalized Medicine Research Project at the Marshfield Clinic (n=421). These findings support the hypothesis that rs1063320 modifies the effect of statin benefit in asthma, and thus may contribute to variation in statin efficacy for the management of this disease.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23993700
- HMS Scholarly Articles 
- SPH Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)